Skip to content

Author

D. Cordelli

We have 5 of 180 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Respiratory Infections in Patients Eligible for Pediatric Palliative Care: An Ongoing Challenge.

BACKGROUND Advances in pediatric care have increased the survival of children with life-limiting conditions, leading to a growing population requiring pediatric palliative care (PPC). Respiratory tract infections are among the leading causes of hospitalization in these patients. This study aimed to describe the feature...

Daniele Zama, Enrico Valerio, Anna Sandoni et al. · 0 citations
Sep 2026

Accuracy of Antibody Testing in Myasthenia Gravis: The ADAM Study.

BACKGROUND AND OBJECTIVES Antibody testing has a pivotal role in the diagnosis of myasthenia gravis (MG). However, there are limited data on the accuracy of the different methods available for acetylcholine receptor (AChR) and muscle-specific kinase (MuSK) autoantibody (Ab) detection in a real-world setting. Our aim wa...

M. P. Giannoccaro, Lucrezia Serra, A. Grondona et al. · 0 citations
Open access Sep 2026

Living with developmental and/or epileptic encephalopathies: exploring health-related quality of life in children, youth, and their families

Attention to non-seizure outcomes in Developmental and/or Epileptic Encephalopathies (DEs, EEs, DEEs) is growing, and there is increasing interest in understanding key determinants of health-related quality of life (HRQoL) in this population. This study investigates personal and family HRQoL in a real-world pedia...

L. Bergonzini, F. Sperandeo, S. Lelli et al. · 0 citations
Open access Aug 2026

Early sodium channel blocker initiation is associated with better outcomes in KCNQ2 disorders.

Earlier SCB initiation was associated with earlier seizure offset and more favourable developmental outcomes, underscoring the importance of early genetic diagnosis and timely SCB therapy, and the use of SCBs, particularly CBZ and OXC, as first-line therapy in (LOF) KCNQ2-DEE and SeL(F)NE is supported.

C. Millevert, M. Hairabedian, Samuel Dahan et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.